PL1616007T3 - Inhibitory proteinowe proteazy i ich wykorzystanie - Google Patents

Inhibitory proteinowe proteazy i ich wykorzystanie

Info

Publication number
PL1616007T3
PL1616007T3 PL04725742T PL04725742T PL1616007T3 PL 1616007 T3 PL1616007 T3 PL 1616007T3 PL 04725742 T PL04725742 T PL 04725742T PL 04725742 T PL04725742 T PL 04725742T PL 1616007 T3 PL1616007 T3 PL 1616007T3
Authority
PL
Poland
Prior art keywords
protease
inhibitor proteins
inhibitor
proteins
Prior art date
Application number
PL04725742T
Other languages
English (en)
Inventor
David Deperthes
Sylvain Cloutier
Original Assignee
Univ Lausanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Lausanne filed Critical Univ Lausanne
Publication of PL1616007T3 publication Critical patent/PL1616007T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL04725742T 2003-04-04 2004-04-05 Inhibitory proteinowe proteazy i ich wykorzystanie PL1616007T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46034503P 2003-04-04 2003-04-04
PCT/IB2004/001040 WO2004087912A1 (en) 2003-04-04 2004-04-05 Inhibitor proteins of a protease and use thereof
EP04725742.3A EP1616007B1 (en) 2003-04-04 2004-04-05 Inhibitor proteins of a protease and use thereof

Publications (1)

Publication Number Publication Date
PL1616007T3 true PL1616007T3 (pl) 2013-12-31

Family

ID=33131923

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04725742T PL1616007T3 (pl) 2003-04-04 2004-04-05 Inhibitory proteinowe proteazy i ich wykorzystanie

Country Status (19)

Country Link
US (1) US8975370B2 (pl)
EP (1) EP1616007B1 (pl)
JP (1) JP4754478B2 (pl)
KR (1) KR101296367B1 (pl)
CN (1) CN1798838B (pl)
AU (1) AU2004225718B2 (pl)
BR (1) BRPI0409557B8 (pl)
CA (1) CA2521410C (pl)
CY (1) CY1114526T1 (pl)
DK (1) DK1616007T3 (pl)
ES (1) ES2431548T3 (pl)
IL (1) IL171158A (pl)
MX (1) MXPA05010574A (pl)
NO (1) NO334459B1 (pl)
PL (1) PL1616007T3 (pl)
PT (1) PT1616007E (pl)
SG (1) SG161106A1 (pl)
SI (1) SI1616007T1 (pl)
WO (1) WO2004087912A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064605A2 (en) 2002-01-28 2003-08-07 Ambion, Inc. Crude biological derivatives competent for nucleic acid detection
WO2006090282A2 (en) * 2005-02-28 2006-08-31 Universite De Lausanne Recombinant inhibitor proteins of an hk14 protease and use thereof
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
US20110130338A1 (en) * 2008-01-21 2011-06-02 Dermadis Sa Use of serine protease inhibitors in the treatment of skin diseases
US8211637B2 (en) * 2008-12-19 2012-07-03 Life Technologies Corporation Proteinase K inhibitors, methods and compositions therefor
KR20120093754A (ko) * 2009-03-10 2012-08-23 메드 디스커버리 에스에이 세린 프로테아제 저해제의 호중구감소증 치료에서의 용도
US8652793B2 (en) * 2011-05-26 2014-02-18 Baxter International Inc. Solid phase-bound elastase-binding assay for the measurement of alpha1-antitrypsin activity
CN103044542B (zh) * 2012-08-17 2015-08-19 常熟理工学院 鲫鱼卵中丝氨酸蛋白酶抑制剂及其基因和应用
CN117169519B (zh) * 2023-10-26 2024-01-30 艾康生物技术(杭州)有限公司 用于检测样本中tt3和/或tt4的解离剂和试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE69033699T2 (de) 1989-03-06 2001-05-23 The Board Of Regents Of The University Of Texas System, Austin Gegenüber eigenen inhibitoren resistente t-pa mutanten
US5827662A (en) * 1989-06-23 1998-10-27 The Trustees Of The University Of Pennsylvania Methods for detecting genetic mutations resulting in protease inhibitor insufficiencies
US5612194A (en) * 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
US5723316A (en) * 1989-06-23 1998-03-03 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having chymase inhibiting activity
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE275583T1 (de) 1994-01-11 2004-09-15 Dyax Corp KALLIKREINHEMMENDE ßKUNITZ-DOMÄNEß-PROTEINE UND DERIVATEN DAVON
US6284873B1 (en) 1999-03-12 2001-09-04 Hybritech Incorporated Complex of human kallikrein 2 (hK2) and protease inhibitor-6 (PI-6) in prostate tumor tissue and methods of using the complex

Also Published As

Publication number Publication date
CY1114526T1 (el) 2016-10-05
CN1798838B (zh) 2012-01-04
CA2521410C (en) 2014-06-03
US8975370B2 (en) 2015-03-10
NO334459B1 (no) 2014-03-10
JP4754478B2 (ja) 2011-08-24
KR101296367B1 (ko) 2013-08-14
CA2521410A1 (en) 2004-10-14
KR20060010740A (ko) 2006-02-02
ES2431548T3 (es) 2013-11-26
EP1616007A1 (en) 2006-01-18
WO2004087912A1 (en) 2004-10-14
BRPI0409557B8 (pt) 2021-05-25
NO20055210L (no) 2005-12-23
NO20055210D0 (no) 2005-11-04
SG161106A1 (en) 2010-05-27
CN1798838A (zh) 2006-07-05
AU2004225718A1 (en) 2004-10-14
DK1616007T3 (da) 2013-10-28
PT1616007E (pt) 2013-10-28
BRPI0409557A (pt) 2006-04-18
IL171158A (en) 2011-05-31
WO2004087912A8 (en) 2005-01-20
EP1616007B1 (en) 2013-07-24
SI1616007T1 (sl) 2013-12-31
JP2006523097A (ja) 2006-10-12
US20060269536A1 (en) 2006-11-30
BRPI0409557B1 (pt) 2019-07-23
AU2004225718B2 (en) 2009-11-05
MXPA05010574A (es) 2006-03-09

Similar Documents

Publication Publication Date Title
AU2003221786A1 (en) Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
AU2003303128A8 (en) Inhibitors and methods of use thereof
EP1507756A4 (en) CCR9 INHIBITORS AND USE THEREOF
GB0125445D0 (en) Protease Inhibitors
EP1538907A4 (en) FTSZ-HEMMER AND ITS USE
PL370766A1 (pl) Podstawione 2-aminocykloalkanokarboksyamidy i ichzastosowanie jako inhibitorów proteaz cysteinowych
EP1549614A4 (en) VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
EP1499336A4 (en) PROTEASE INHIBITORS
EP1694647A4 (en) INHIBITORS OF CYSTEINE PROTEASES OF THE CATHEPSIN TYPE
EP1476150A4 (en) CARBOXY FULLERES AND USE METHOD THEREFOR
IL165084A0 (en) Peptide compounds and their use as protease substrates
EP1673336A4 (en) INHIBITORS OF CATHEPSIN AND CYSTEINE PROTEASE
EP1663279A4 (en) MODIFIED PROTEASE INHIBITORS
ZA200510465B (en) Use of a novel eimeria gene and corresponding protein
AU2003234630A1 (en) Cysteine protease inhibitors
EP1704142A4 (en) PROTEASE INHIBITORS
PL1616007T3 (pl) Inhibitory proteinowe proteazy i ich wykorzystanie
AU2003269984A8 (en) Protease inhibitors
AU2003258941A8 (en) Metalloproteinase inhibitors and intermediates for preparation thereof
AU2003300800A8 (en) Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
EP1401453A4 (en) PROTEASE INHIBITORS
GB0411145D0 (en) Protease inhibitors and their therapeutic applications
AU2003277878A1 (en) Arylsulfonylhydroxamic acid and amide derivatives and their use as protease inhibitors
AU2003304374A8 (en) Peptide inhibitors of beta-lactamases
AU2003263738A8 (en) Protease inhibitors